Drug intelligence / Profile preview

(2R)-2-acetamido-3-(octadecyloxy)propyl 2-(methylsulfanyl)ethyl hydrogen phosphate

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is a synthetic phosphoethanolamine derivative, classified as a small molecule. It features an acetamido group, an octadecyloxy chain, and a methylsulfanyl ethyl hydrogen phosphate moiety. The molecule is experimental and not approved for clinical use in any country. Its primary known biological interaction is with membrane-associated phospholipase A2, suggesting it may act as a substrate or modulator of this enzyme. No clinical indications or therapeutic uses are established for this compound[1].

Other names: 1-octadecyl-2-acetamido-2-deoxy-sn-glycerol-3-phosphoethylmethyl sulfide

Targets

PLA2G2A (Secretory phospholipase A2 group IIA)PLA2 (Phospholipase A2 group IID)

Beyond the preview

Go deeper on (2R)-2-acetamido-3-(octadecyloxy)propyl 2-(methylsulfanyl)ethyl hydrogen phosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on (2R)-2-acetamido-3-(octadecyloxy)propyl 2-(methylsulfanyl)ethyl hydrogen phosphate.